CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines
Authors:
- the CPNDS Clinical Recommendations GroupTGthe CPNDS Clinical Recommendations Group
- Britt I. DrögemöllerBDBritt I. Drögemöller
- Colin J. D. RossCRColin J. D. Ross
- Bruce C. CarletonBCBruce C. Carleton
- 8 November 2018
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 173 (3) , 521-532
Abstract
Purpose Tamoxifen is one of the principal treatments for estrogen receptor (ER)-positive breast cancer. Unfortunately, between 30 and 50% of patients receiving this hormonal therapy relapse. Since CYP2D6 genetic variants have been reported to play an important role in survival outcomes after treatment with tamoxifen, this study sought to summarize and critically appraise the available scientific evidence on this topic. Methods A systematic literature review was conducted to identify studies investigating associations between CYP2D6 genetic variation and survival outcomes after tamoxifen treatment. Critical appraisal of the retrieved scientific evidence was performed, and recommendations were developed for CYP2D6 genetic testing in the context of tamoxifen therapy. Results Although conflicting literature exists, the majority of the current evidence points toward CYP2D6 genetic variation affecting survival outcomes after tamoxifen treatment. Of note, review of the CYP2D6 genotyping assays used in each of the studies revealed the importance of comprehensive genotyping strategies to accurately predict CYP2D6 metabolizer phenotypes. Conclusions and recommendations Critical appraisal of the literature provided evidence for the value of comprehensive CYP2D6 genotyping panels in guiding treatment decisions for non-metastatic ER-positive breast cancer patients. Based on this information, it is recommended that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers.Keywords
Funding Information
- Canadian Institutes of Health Research (FRN 114403)
This publication has 75 references indexed in Scilit:
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 TrialJNCI: Journal of the National Cancer Institute, 2012
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) GenotypeClinical Pharmacology & Therapeutics, 2011
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer OutcomesClinical Pharmacology & Therapeutics, 2011
- The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancerBritish Journal of Cancer, 2010
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Going from evidence to recommendationsBMJ, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971